The prespecified analysis of the FINEARTS-HF trial, published in The Lancet, showed that finerenone, a mineralocorticoid receptor antagonist, significantly reduced the incidence of new-onset diabetes in patients with heart failure. Researchers found a 24% reduction in the risk of developing new-onset diabetes in the finerenone group compared with placebo, indicating a meaningful clinical benefit. These findings support finerenone as a potential treatment option for heart failure, given its ability to mitigate the risk of diabetes, a common comorbidity that exacerbates heart failure outcomes. The effects of finerenone were consistent across key subgroups, including those with varying levels of heart failure severity, and were found to be additive with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors.